Kleinostheim, Germany, 28th March 2011 – curasan AG, which is listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has received European approval for a novel synthetic bone regeneration material.

Osseolive® is a bioactive, poly-crystalline calcium-alkali-phosphate ceramic, which has a stimulating effect on bone formation as well as on bone mineralisation.

“With Osseolive® emerging from our well-stocked development pipeline, we now have an ideal extension to our tricalcium-phosphate products”, stated Hans Dieter Rössler, CEO. Osseolive® has been specifically designed for the treatment of large defects in combination with bone growth supporting substances, such as bone marrow aspirate, stem cells, and bone morphogenetic proteins (BMPs).”

Background information about curasan AG:

Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading companies in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. Some of these various new developments are ready yet for market rollout. These biomaterials will be marketed globally by well-positioned contractual partners. Further products will follow until end of 2012. www.curasan.com